SCHEMBL13627285

SCHEMBL13627285

CCONC(=O)CCCCCCC(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.68
LMNA P02545 2/20 0.68
NPSR1 Q6W5P4 2/20 0.68
HTR1A P08908 3/20 0.60
HTR7 P34969 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
HDAC1 Q13547 2/20 0.55
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
PLA2G1B P04054 1/20 0.50
TSHR P16473 1/20 0.50
ATG4B Q9Y4P1 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
POLB P06746 1/20 0.50
CACNA1G O43497 1/20 0.49
USP2 O75604 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12432013 0.85 MAPT (0.76) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL1374706 0.83 MAPT (0.78) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL1374177 0.83 MAPT (0.78) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL9565881 0.83 MAPT (0.82) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL7698031 0.83 MAPT (0.82) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL13080421 0.83 MAPT (0.82) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL7696482 0.83 MAPT (0.82) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL10726722 0.83 MAPT (0.82) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL1374666 0.82 MAPT (0.72) MAPTLMNANPSR1HTR1AHTR7
SCHEMBL1374776 0.82 MAPT (0.76) MAPTLMNANPSR1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291978-A1 Enzyme Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291978-A1 Enzyme Inhibitors HAT1, NR2E1, NR2C2 MAPT 4873/4885LMNA 1371/4885NPSR1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.